Retatrutide appears to be a new medication who makes tirzepatides for Eli Lilly in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, demonstrates promising results in investigations. By stimulating these receptors, Retatrutide suppresses appetite, {promotesglucose regulation, and ultimately lea